"These executive orders are
consistent with the previous [drug pricing] blueprint adopted by the
Administration and debated in part in Congress. But having the authority to
make quick changes doesn't mean doing so is a good idea, especially so close to
an election."
— Marc Samuels, CEO of ADVI and a former adviser to Presidents
George H.W. Bush and George W. Bush, talked with AIS's Health Plan Weekly about
why the Trump administration's latest drug pricing executive orders will likely
draw strong opposition.
No comments:
Post a Comment